Globus Medical Q3 EPS Forecast Increased by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research boosted their Q3 2025 EPS estimates for shares of Globus Medical in a note issued to investors on Thursday, December 12th. Zacks Research analyst R. Department now expects that the medical device company will post earnings of $0.84 per share for the quarter, up from their previous forecast of $0.83. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share. Zacks Research also issued estimates for Globus Medical’s Q2 2026 earnings at $0.98 EPS.

Globus Medical (NYSE:GMED) last announced its earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.18. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. The business had revenue of $625.71 million for the quarter, compared to analyst estimates of $604.69 million. During the same period in the previous year, the company earned $0.57 earnings per share. The company’s revenue for the quarter was up 63.1% compared to the same quarter last year.

A number of other analysts have also issued reports on the stock. Roth Mkm restated a “buy” rating and issued a $100.00 price target on shares of Globus Medical in a research note on Wednesday, November 6th. Bank of America raised their price objective on shares of Globus Medical from $55.00 to $80.00 and gave the stock an “underperform” rating in a report on Wednesday, November 6th. Morgan Stanley upgraded shares of Globus Medical from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $83.00 to $100.00 in a research note on Monday, December 2nd. StockNews.com downgraded Globus Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Piper Sandler boosted their price objective on Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.18.

Globus Medical Stock Down 0.4 %

GMED stock opened at $82.42 on Monday. The stock’s 50 day moving average is $78.81 and its two-hundred day moving average is $72.88. Globus Medical has a 52-week low of $49.14 and a 52-week high of $87.22. The company has a market capitalization of $11.22 billion, a PE ratio of 123.01, a P/E/G ratio of 1.99 and a beta of 1.19.

Insider Buying and Selling

In other Globus Medical news, CEO Daniel T. Scavilla sold 60,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total transaction of $4,801,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David D. Davidar sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the completion of the sale, the director now owns 536,275 shares in the company, valued at $40,242,076. The trade was a 5.30 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 97,500 shares of company stock valued at $7,674,950. Insiders own 18.54% of the company’s stock.

Institutional Trading of Globus Medical

Hedge funds have recently added to or reduced their stakes in the business. State Street Corp lifted its stake in shares of Globus Medical by 2.3% in the 3rd quarter. State Street Corp now owns 3,570,726 shares of the medical device company’s stock worth $255,450,000 after acquiring an additional 81,371 shares during the period. Burgundy Asset Management Ltd. raised its holdings in Globus Medical by 1.4% during the second quarter. Burgundy Asset Management Ltd. now owns 2,514,891 shares of the medical device company’s stock worth $172,245,000 after purchasing an additional 35,054 shares in the last quarter. Geode Capital Management LLC lifted its position in Globus Medical by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,885,061 shares of the medical device company’s stock worth $134,893,000 after purchasing an additional 21,935 shares during the period. Magnetar Financial LLC lifted its position in Globus Medical by 1.7% in the second quarter. Magnetar Financial LLC now owns 1,718,487 shares of the medical device company’s stock worth $117,699,000 after purchasing an additional 29,200 shares during the period. Finally, Geneva Capital Management LLC boosted its stake in Globus Medical by 1.1% during the 3rd quarter. Geneva Capital Management LLC now owns 1,598,130 shares of the medical device company’s stock valued at $114,330,000 after purchasing an additional 18,117 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.